The present study is the first to demonstrate that deAND ameliorates steatohepatitis, liver fibrosis, and liver damage partially by enhancing hepatic Nrf2-mediated downstream antioxidant enzyme activities and suppressing NLRP3 inflammasome activation in HFHC diet-induced fatty liver disease. This evidence concerns the gene NFE2L2 and fatty liver disease.